Cardiovascular · Omega-3 Fatty AcidsRegulatory Approvalcommercialmid-term

Aurobindo Pharma's ANDA218949 for Icosapent Ethyl Receives AP Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/30/2026, 6:31:16 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's Abbreviated Approval of Aurobindo Pharma's ANDA218949 for Icosapent Ethyl signifies a new competitive entrant in the cardiovascular market. This development necessitates a reassessment of market strategies by existing players to maintain their market share and pricing integrity. Regulatory context from FDA (FDA AP — ICOSAPENT ETHYL (ORIG)) supports the near-term read. Assessment grounded in 24 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Icosapent Ethyl. The strongest clinical anchor is A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Omega-3 Fatty Acids, 8 regulatory and 7 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval allows Aurobindo to enter the market for Icosapent Ethyl, increasing competition against existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ICOSAPENT ETHYL (ORIG) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The AP status indicates a streamlined pathway for Aurobindo, which may influence regulatory strategies for other companies seeking to enter similar markets.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (CV CARE: CardioVascular Care in PC Patients) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatia) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Aurobindo's entry could disrupt pricing and market dynamics, potentially affecting revenue streams for current market leaders in the Icosapent Ethyl segment.
Portfolio teams should assess the impact of Aurobindo's entry on market share and pricing strategies for Icosapent Ethyl.

What Would Change This Assessment

This becomes more urgent if Monitor the market launch timeline and any potential pricing strategies from Aurobindo Pharma.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ICOSAPENT ETHYL (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Pharmacy Compounding Advisory Committee Roster
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
CV CARE: CardioVascular Care in PC Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Community Blood Pressure Screening and Cardiovascular Risk Assessment in Croatia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Khoury's Bone Shell Technique Versus Titanium-Reinforced Polytetrafluoroethylene for Augmentation of Horizontal Deficiency in Posterior Mandible (Histomorphometry Analysis): A Randomized Clinical Tria
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Tioprinin for Treatment of Cystinosis
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for TRYNGOLZA Autoinjector Submission
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
m6A methylation of circKPNA2 promotes colorectal carcinogenesis by activating the RIN1-Ras pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
existing competitors

Commercial impact

medium

Aurobindo's entry could disrupt pricing and market dynamics, potentially affecting revenue streams for current market leaders in the Icosapent Ethyl segment.

Regulatory impact

medium

The AP status indicates a streamlined pathway for Aurobindo, which may influence regulatory strategies for other companies seeking to enter similar markets.

What to watch

Monitor the market launch timeline and any potential pricing strategies from Aurobindo Pharma.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.